A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

Current Medical Research and Opinion

Volumn 27, Issue 6, 2011, Pages 1157-1168

  Hutchins, Valerie ^a   Zhang, Bin ^b   Fleurence, Rachael L ^a   Krishnarajah, Girishanthy ^c   Graham, John ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Adherence; Diabetes; Economics; Fixed dose combination; Patient satisfaction; Quality of life

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; METFORMIN; MONENSIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

BUDGET; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; INSULIN TREATMENT; LIFE EXPECTANCY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PILL; QUESTIONNAIRE; REVIEW; SELF REPORT; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 79956078204     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.570745     Document Type: Review

References (43)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998: 21:1414-31 (Pubitemid 28405191)
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, 2008
3. Goldney RD, Phillips PJ, Fisher LJ, et al. Diabetes, depression, and quality of life: a population study. Diabetes Care 2004;27:1066-70 (Pubitemid 38579767)
4. Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31 596-615
5. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31 (Suppl 1):S12-54
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
7. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995;44:1249-58
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
9. Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther 2005;27:1548-61 (Pubitemid 41739491)
10. Chou HS, Palmer JP, Jones AR, et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab 2008;10:626-37 (Pubitemid 352044292)
11. Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006;8:650-60 (Pubitemid 44515562)
12. Comaschi M, Demicheli A, Di Pietro C, et al. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:387-98 (Pubitemid 47340089)
13. Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes 2008;116:6-13 (Pubitemid 351270902)
14. Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2006;8:156-63
15. American Diabetes Association Meeting Abstracts. Diabetes 1998-2003; 48-53(Suppl)
16. Blonde L, Wogen J, Kreilick C, et al. Greater reductions in A1c in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003;5:424-31 (Pubitemid 37483604)
17. Pan F, ChernewME, FendrickAM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:611-14
18. Brook RA, Kleinman NL, Wingenbach D, et al. Medication possession ratio and health benefit cost comparisons in type 2 diabetes patients using fixed-and loose-dose thiazolidinedione combination products [abstract]. Diabetes 2008;57:1214-P
19. Patel BV, Leslie RS, Aranda GA. Retrospective comparison of compliance to fixed-dose combination versus single agent combination therapy for the treatment of diabetes [abstract]. ISPOR 12th Annual International Meeting. Arlington, VA, USA; 2008:PDB14
20. Vanderpoel DR, Hussein MA, Watson-Heidari T, et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 2004;26:2066-75 (Pubitemid 40353616)
21. Steel R, Torrie J. Analysis of Covariance Principles and Procedures of Statistics: a Biometrical Approach, 2nd edn. New York: McGraw Hill, 1980: 429-58
22. Cheong C, Barner JC, Lawson KA, et al. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008;30:1893-907
23. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7 (Pubitemid 34275867)
24. Home PD, Bailey CJ, Donaldson J, et al. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with type 2 diabetes. Diabet Med 2007;24:618-25 (Pubitemid 46808868)
25. Raskin P, Lewin A, Reinhardt R, et al. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab 2009; 11:865-73
26. Raskin P, Lewin A, Reinhardt R, et al. Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes Obes Metab 2009;11:947-52
27. Shaw M, Talley NJ, Adlis S, et al. Development of a digestive health status instrument: Tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998;12:1067-78 (Pubitemid 28508720)
28. Duh MS, Gosselin A, Beaulieu N, et al. Comparison of resources utilization (ru) and costs in drug-naive type 2 diabetes (t2d) patients (pts) treated with rosiglitazone (rsg)/metformin (met) as fixed-dose combination (fdc) vs. sulfonylurea (su) plus metformin (met) as combination therapy (ct) [abstract] Diabetes 2007;56:2202-PO
29. Delea T, Arondekar B, Kartashov A, et al. Add-on therapy with rosiglitazone (rsg)/metformin (met) as a fixed-dose combination (fdc) vs rsg plus met or rsg plus sulfonylurea (su) as separate pills (sp): Retrospective study of outcomes and costs [abstract]. Diabetes 2007;56:2200-P0
30. Palmer AJ, Roze S, Valentine WJ, et al. The core diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(Suppl 1):S5-26
31. Lang D, Lopert R, Hill S. Use of pharmoeconomics in prescribing research. Part 5: modelling\beyond clinical trials. J Clin Pharm Ther 2003;28:433-9 (Pubitemid 37352454)
32. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38 (Pubitemid 24013155)
33. Stevens RJ, Kothari V, Adler Al, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9 (Pubitemid 33135349)
34. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81 (Pubitemid 30090804)
35. Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-43 (Pubitemid 19055344)
36. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8
37. Cabrieres L, Roze S, Comte S, et al. Cost-effectiveness of switching patients to combined glyburide and metformin (Glucovance) when poorly controlled with metformin monotherapy: A French analysis [abstract]. 38th Annual Meeting of the EASD. Budapest, Hungary 2002:0930
38. Garber AJ, Donovan Jr DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003;88:3598-604 (Pubitemid 37034501)
39. Cugnardey N, Roze S, Palmer AJ, et al. Fixed combination metformin plus glibenclamide (Glucovance®) is cost and life saving compared to metformin plus rosiglitazone in type 2 diabetes patients in France [abstract]. ISPOR 8th Annual European Congress. Florence, Italy 2005:PDB25
40. Lobo F, Thomas S, Sill B, et al. Budget impact of adding fixed-dose combination of pioglitazone plus glimepiride to a formulary plan over a three-year time frame [abstract]. ISPOR 13th Annual International Meeting. Toronto, Ontario, Canada 2008:PDB14
41. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res;22:151-73
42. Song F, Parekh-Bhurke S, Hooper L, et al. Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies. BMC Med Res Methodol 2009;9:79
43. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Intervention (updated September 2008) The Cochrane Collaboration, 2008